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ABSTRACT
Introduction Recent evidence suggests that ethnic 
minority groups are disproportionately at increased risk 
of hospitalisation and death from SARS- CoV-2 infection. 
Population- based evidence on potential explanatory factors 
across minority groups and within subgroups is lacking. 
This study aims to quantify the association between 
ethnicity and the risk of hospitalisation and mortality due 
to COVID-19.
Methods and analysis This is a retrospective cohort 
study of adults registered across a representative and 
anonymised national primary care database (QResearch) 
that includes data on 10 million people in England. 
Sociodemographic, deprivation, clinical and domicile 
characteristics will be summarised and compared across 
ethnic subgroups (categorised as per 2011 census). Cox 
models will be used to calculate HR for hospitalisation 
and COVID-19 mortality associated with ethnic group. 
Potential confounding and explanatory factors (such as 
demographic, socioeconomic and clinical) will be adjusted 
for within regression models. The percentage contribution 
of distinct risk factor classes to the excess risks seen in 
ethnic groups/subgroups will be calculated.
Ethics and dissemination The study has undergone 
ethics review in accordance with the QResearch 
agreement (reference OX102). Findings will be 
disseminated through peer- reviewed manuscripts, 
presentations at scientific meetings and conferences with 
national and international stakeholders.
INTRODUCTION
Recent reports and early observational data 
suggest that the prevalence of COVID-19, 
hospitalisation and deaths are dispropor-
tionately higher among ethnic minority 
populations.1–3 Potential speculative mech-
anisms include genetic variations, comor-
bidities, cultural or behavioural patterns, 
occupational factors, social constructs and 
inequalities. In the UK, people with ethnic 
minority backgrounds constitute 16% of 
the population, but the Intensive Care 
National Audit and Research Centre reports 
that over 30% of people admitted to inten-
sive care with COVID-19 were from these 
backgrounds.4 5 Furthermore, 64% of 119 
National Health Service (NHS) staff who died 
from COVID-19 as of 30 April 2020 were from 
ethnic minority backgrounds.6 A rapid review 
on the subject led by Khunti et al suggests that 
there are also variations in mortality within 
broad ethnic minority groups.3 Most national 
and international data on COVID-19 are 
aggregated and have not reported outcome 
by ethnic group sufficiently to permit exam-
ination of within- group differences.
At the time of submitting this manu-
script, a limited number of population- 
based cohort studies regarding COVID-19 
have been undertaken worldwide. In the 
USA, a study within the largest healthcare 
system, the Veterans Health Administra-
tion, reports excess mortality among ethnic 
minorities.7 In the UK, the availability of 
high- quality, large (multimillion) databases 
that have linkage across varying information 
sources are starting to examine this associa-
tion further. Large primary care databases 
have been used, for example, to develop risk 
prediction models for adverse COVID-19 
outcomes in the general population and to 
undertake large- scale epidemiological eval-
uations of COVID-19 risk factors and drug 
safety.8 In the UK, two large cohorts have 
reported to date on the association between 
ethnicity and COVID-19- related mortality 
outcomes: the OpenSAFELY Collaborative of 
Strengths and limitations of this study
 ► The QResearch database includes a large sample 
that represents 18% of the English population.
 ► As data are based on primary care clinical entries, 
recording of exposures and outcomes may vary in 
completeness.
 ► Total COVID-19 cases in the cohort will be underes-
timated as national systematic testing is still being 



















pen: first published as 10.1136/bm





2 Dambha- Miller H, et al. BMJ Open 2021;11:e045286. doi:10.1136/bmjopen-2020-045286
Open access 
23 million UK records and the NHS England cohort study 
of over 61 million people. The OpenSAFELY consortium 
reported that people with black or Asian backgrounds 
have a higher risk of death from COVID-19 compared 
with people who are white.9 Data from NHS England 
also showed a greater mortality risk for Asian (HR 1.3) 
and black (HR 1.7) backgrounds. Further analysis of 
these data, carried out by the Office for National Statis-
tics (ONS), showed that the mortality risk in black men 
and women was 1.9 times higher than in white individ-
uals. Contradictory to a previous study in a smaller, single- 
state US health system database, both studies identify a 
persisting excess risk of COVID-19- specific mortality after 
accounting for known risk factors, including age, sex, 
deprivation and comorbidities such as obesity, diabetes 
and cardiovascular disease. The causes of these excess 
risks are poorly understood, incompletely quantified and 
may vary within and between ethnic minority groups.
Previous studies have been limited by the lack of consid-
eration of additional potential explanatory variables, 
such as specific medications, rarer comorbidities,10 social 
differences such as household structure, or vaccination 
status.9 A recent population- based study, for example, 
identified a significant interaction between ethnicity and 
ACE inhibitors/angiotensin receptor blockers for COVID-
19.11 Several smaller studies have also suggested a role of 
glucose- lowering medications in the ethnicity- dependent 
variations observed in COVID-19 outcomes.12 13 Single- 
centre studies and case series are providing additional 
insights into the potential interaction between ethnicity 
and haematological disorders, such as sickle cell disease,10 
in relation to COVID-19. Population- based studies with 
adequate number of people from different ethnic groups 
that consider these wider variables are necessary to eval-
uate the explanatory factors surrounding this risk. More-
over, earlier studies have been limited, and larger cohorts 
that extend to the wider English population are needed 
for validation and to allow generalisability of findings. 
Accordingly, in this study we aim to quantify ethnic group- 
specific risk of SARS- CoV-2 infection, COVID-19 mortality 
and COVID-19 hospital admission, and examine the 
effect of non- modifiable (eg, age and sex) and explan-




This is a retrospective cohort study from electronic 
general practice (GP) records linked at the individual 
level to hospital admissions, SARS- CoV-2 testing and 
death registry databases.
Data sources
We will use the QResearch national primary care data-
base, which includes 1205 GPs with 10 million records. 
The sample represents 18% of the English popula-
tion. QResearch holds data on a heterogeneous and 
representative ethnic minority population, with compre-
hensive information on a range of clinical and socioeco-
nomic factors. Further details on the population included 
within the QResearch database and representative are 
updated regularly on the database website.14 Additional 
databases may be included as these become available.
Study period
We will include the period from the date of the first case 
of COVID-19 in the UK (24 January 2020) until death, 
deregistration or 30 October 2020.
Inclusion criteria
We will include all adults aged over 18 years registered 
with a GP practice during the study period and for at least 
12 months prior to inclusion. The GP practice registra-
tion needs to be linked to a relevant clinical system (ie, 
EMIS).
Primary outcome
The primary outcome will be COVID-19- related mortality 
as recorded in the primary care records and linked 
to ONS data. Details on the extent of linkage available 
within the database have been reported previously and 
can be found in full on the QResearch website.15 COVID-
19- related mortality will be defined as the presence of 
U07.1 or U07.2 on death certificates or death from any 
cause in a patient with a confirmed positive SARS- CoV-2 
test in the immediately preceding 28 days.
Secondary outcomes
COVID-19 hospitalisation was defined as hospitalisation 
with confirmed or suspected COVID-19 (as per Interna-
tional Classification of Diseases-10 codes), or new hospi-
talisation in a patient with a positive SARS- CoV-2 test in 
the immediately preceding 14 days.
Ethnicity definition
A self- reported ethnic group is recorded in medical 
records. QResearch has ethnicity records in 80% of all 
patients. Ethnicity will be considered in two ways: first 
in 9 high- level categories: white, Indian, Bangladeshi, 
Pakistani, other Asian, black African, black Caribbean, 
Chinese and ‘Other’; and then, if numbers allow, further 
subdivided into the standard 17 categories used by ONS 
and include the following: English/Welsh/Scottish/
Northern Irish/British, Irish, Gypsy or Irish Traveller, 
any other white background, white and black Caribbean, 
white and black African, white and Asian, any other 
mixed/multiple ethnic backgrounds, Indian, Pakistani, 
Bangladeshi, Chinese, any other Asian background, 
African, Caribbean, any other black/African/Caribbean 
background, Arab or any other ethnic group.
Explanatory variables
We will extract data (where available) corresponding to 
the following potential exposure and confounding vari-
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August 2020, but will be kept under review as new infor-
mation arises in the literature:
Demographic variables
 ► Ethnicity (9 categories, and numbers permitting, 
subdivision into 17 ONS groups).
 ► Sex.
 ► Age (continuous variable).
 ► Geographical region.
Concurrent medication
 ► Glucose- lowering medications (metformin, sulfony-
lureas, thiazolidinedione, SGLT-2 inhibitors, DPP-4 
inhibitors, GLP- 1R agonists) and insulin therapy.
 ► Hormone therapy (in women).
Clinical/blood test assessments
 ► Body mass index.
 ► Blood pressure (systolic and diastolic).
 ► Haemoglobin A1c.
 ► Total cholesterol and low- density lipoprotein.
 ► Liver function tests, including alanine 
aminotransferase.
 ► Estimated glomerular filtration rate.
Comorbidities
 ► Sickle cell status.10
 – Sickle trait.
 – Sickle cell disease.
 ► Diabetes (type 1 and type 2 separately).13 16
 – Diabetes duration.
 ► Chronic kidney disease (CKD).
 – CKD stage 3.
 – CKD stage 4.
 – CKD stage 5 (including those requiring dialysis or 
ever receiving a transplant).
 ► Cancer.
 – Active or past haematological or solid cancer.
 ► Transplant (solid organ or bone marrow).
 ► Vaccination status.
Key confounding variables
Demographic variables
 ► Quintile of Townsend Deprivation Score: this is an 
area- level quintile score based on the patient’s post-
code. Originally developed by Townsend, it includes 
unemployment (as a percentage of those aged 16 and 
over who are economically active); non- car ownership 
(as a percentage of all households); non- home owner-
ship (as a percentage of all households); and house-
hold overcrowding. These variables are measured for 
a given area of approximately 120 households, via 
the 2011 census, and combined to give a ‘Townsend 
score’ for that area. A higher Townsend score implies 
a greater level of deprivation.
 ► Residence type.
 – Lives in a care home (nursing home or residential 
care).
 – Homelessness.
 – Lives in own home.
 ► Household characteristics.
 – Age of household members.
 – Number of household inhabitants.
Lifestyle factors
 ► Smoking status coded as non- smoker, ex- smoker, light 
(<10 cigarettes/day), moderate (10–19) and heavy 
(20+).
Comorbidities
 ► Cardiovascular disease.
 ► Hypertension.
 ► Chronic respiratory disease.
 ► Liver cirrhosis.
 ► Depression.
 ► Dementia.
 ► Other chronic neurological diseases.
 ► Severe mental health illness.
 ► Learning disability.
Concurrent medication
 ► Lipid- lowering medications.
 ► Antihypertensive medications.
All predictor variables will be based on the latest coded 
information recorded in the GP record prior to entry to 
the cohort.
Sample size calculation
As of 9 August 2020, there had been 41 686 COVID-19 
deaths in England out of a total population of 56 million. 
Assuming a 0.074% mortality rate in the general popu-
lation, to detect a conservative estimate of an HR of 1.2 
for COVID-19 mortality in the ethnic minority population 
that represents 18.6% of the study population (based on 
recent QResearch studies) with 90% power and a signif-
icance level of 0.01, we would need a sample size of 3 
995 350 individuals with 2957 COVID-19 deaths. As recent 
studies of COVID-19 using QResearch have included 
cohorts of over 8 million adults with over 5000 COVID-19 
deaths, even with 40% missing data, our study is suffi-
ciently powered.
Statistical methods
Participant characteristics will be summarised by ethnicity, 
age, sex, comorbidities and outcome with appropriate 
summary statistics. We will describe SARS- CoV-2 infection, 
COVID-19 hospitalisation and COVID-19 mortality rates 
in the general population and stratify this by ethnicity. 
Plots of survival curves stratified by ethnic group will be 
generated using the Kaplan- Meier method and compared 
with the log- rank test. We will use Cox proportional 
hazards models to estimate unadjusted and adjusted HRs 
for the associations between ethnicity and the outcomes of 
interest. When proportional hazards assumptions are not 
met, we will consider using more flexible models which 
do not assume proportionality of hazards, for example, 
flexible parametric survival models. Subsequently, we will 
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any observed increased mortality or hospitalisation risks 
in people of non- white ethnicity. For all analyses, we will 
conduct complete case analyses, and then separately 
impute for missing values, for example, ethnic group, 
body mass index, deprivation quintile and smoking status, 
using five imputations incorporating all model outcomes 
and predictors with model coefficients and SEs pooled in 
accordance with Rubin’s rules. Data will be analysed using 
STATA V.16. Our study will be conducted and findings 
reported in line with the Strengthening the Reporting of 
Observational Studies in Epidemiology17 and RECORD 
guidelines for observational studies using routinely 
collected health data.18
Patient and public involvement
Patient representatives have been involved in the devel-
opment of the study aims and design. We sought feed-
back from study inception and design from patients and 
the public within the Centre for BME Health, Leicester. 
We additionally have two public representatives as part of 
the study team whose contributions have been acknowl-
edged in the authorship list of this manuscript. They will 
continue to be involved in all stages of the study, with 
additional public and patient views sought for dissemina-
tion strategies.
Ethics and dissemination
The project has been independently peer- reviewed and 
received ethics approval from the QResearch Scientific 
Board (reference OX102). Findings will be disseminated 
through peer- reviewed manuscripts, presentations at 
scientific meetings and conferences with national and 
international stakeholders.
DISCUSSION
Our findings aim to provide rapid evidence on the 
patterns of COVID-19 and associated mortality across and 
within ethnic groups in England. This study will be one of 
the largest COVID-19 cohorts, with a representative popu-
lation across both rural and urban areas. Our cohort size 
will enable us to detect national- level variations within 
ethnic minority subgroups across a large geographical 
area and thus, to some extent, overcome selection bias 
limitations of previous cohort studies. Our findings have 
the potential to inform targeted mitigation public health 
strategies and could alter clinical thresholds for at- risk 
patients presenting with the infection.
As we are using routinely recorded clinical data from 
primary care records rather than prospectively collecting 
the data, we anticipate that our study will be subject to 
limitations. First, the precision and completeness of 
routine NHS patient records will vary, although previous 
work from QResearch suggests that key variables have high 
levels of accuracy and completeness. Second, our sample is 
likely to underestimate the total number of people in the 
population with COVID-19 due to the lack of systematic 
national testing programmes, which are still being rolled 
out, and also due to false- negative test results. There is also 
some evidence that testing rates are lower among ethnic 
minority groups. Our confirmed SARS- CoV-2 infection 
cases will additionally over- represent people with more 
severe disease who died or were hospitalised. During the 
earlier part of the pandemic, testing in the UK was limited 
to the hospital setting and people with COVID-19 who 
were not admitted or recovered (who may be from ethnic 
minority groups) are less likely to be captured in the data. 
Further, the admission criteria for Intensive Care Units 
varied during the course of the pandemic, with partic-
ular characteristics such as older age resulting in a lower 
chance of admission at a time when high admission rates 
were anticipated, which may introduce a selection bias.
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